STAFF PROFILE -
Dr. Christophe Le Tourneau
Roche Fellowship in New Drug Development
I
started a two-year fellowship program as a Clinical Research Fellow in the Robert and Maggie Bras & Family New Drug Development Program at Princess Margaret Hospital in November 2007. My planned date of completion is October 2009. I am currently involved in all aspects of the evaluation and management of patients on early phase clinical trials. In addition, I actively participate in various research activities and am involved in the design and implementation of clinical trial protocols, and clinical, translational and/or laboratory research.
already been published, and a third one is in press about predictives biomarkers of efficacy to anti-EGFR and antiVEGFR agents. Another review about an HDAC inhibitor is being peer-reviewed. The mentorship provided by the staff oncologists in the Drug Development Program will be beneficial to my future career as a clinical investigator in oncology at the Institut Curie in Paris, France. Back to France, I will integrate the clinical trial unit and run the head and neck clinic.
My research projects include a first-in-human phase I trial with a PI3K inhibitor, some phase I/II studies in head and neck cancer involving a pan-HER agent, an antiangiogenic agent and a new taxane, as well as a phase I study of immunotherapy in nasopharyngeal carcinoma. Moreover, I am currently writing as a review on phase I dose escalation methods, and on endpoints in advanced head and neck cancer. Two reviews on targeted agents in head and neck cancer have
STAFF PROFILE -
ROBIN CHEIKEN RN, BSN
R
obin Cheiken graduated Manger responsible for the liaison between the DDP and from Thomas Jefferson the Protocol Information Office at CTEP/NCI-US on University in Philadelphia, protocol Letters of Intent and protocol amendments. Robin Pennsylvania in 1991 with a has experience in conducting multi-centered clinical trial, Bachelor Science Degree in protocol development and data safety review. She conducted Nursing. Robin began her career the training of PMH Phase II Consortium staff throughout in oncology research as a clinical Canada and the US in serious adverse event reporting for trials nurse at the Lombardi NCI sponsored trials. Comprehensive Cancer Center at Georgetown University Medical Robin left PMH briefly to pursue other opportunities in data Center in Washington, DC. In 2000, she accepted the safety review for private industry. She returned to the DDP position as the Serious Adverse Events Manager for the in November 2007 as the Phase I Program Manager. Investigational Drug Branch in CTEP/NCI-US, where she managed the team responsible for the collection, analysis, “It is a privilege to work with an extraordinary group of and timely reporting of serious adverse events (SAE’s) to the physicians, nurses, data managers and pharmacists dedicated Food and Drug Administration (FDA) for CTEP monitored to innovative drug development for cancer therapy”. clinical investigations. Robin joined the Robert & Maggie Bras and Family New Drug Development Program in September 2002 as a Clinical Study Coordinator. In 2005, she was promoted to Assistant “The future always holds something for the man who keeps his faith in it!” - H.L. Hollis